Field Trip Health Ltd. Continues Expansion With Psychedelic-Enhanced Therapy Center in Chicago


Ryan Allway

October 23rd, 2020

Psychedelics


Field Trip Health Ltd. (CSE: FTRP) (“Field Trip”), the global leader in the development and delivery of technology-enabled psychedelic therapies, announced today the opening of their Chicago center. Located at 325 West Huron Street, Suite 603, the Chicago location is the fourth Field Trip Health center to open this year, following Toronto, New York and Los Angeles.

Psychedelic-enhanced psychotherapy has the potential to transform lives, leading to improved well-being,1 optimism2 and increased neural plasticity3 according to multiple evidence-based studies from world-class institutions around the world. Field Trip Health takes a step-by-step, integrated approach to psychedelic-assisted therapies to support those struggling with depression and other mental health challenges.

Within Field Trip Health’s centers, each person’s journey is personalized and influenced by their individual needs and goals to best enable them to heal and grow. Before treatment is approved, each person is screened by Field Trip Health’s team of certified psychiatrists and medical professionals to ensure ketamine-assisted therapy is appropriate.

Once approved for treatment, on arrival at the Chicago location, each person is ushered into a private room where they are set up in a zero gravity chair and, following a short chat with their therapist, the ketamine dose is administered by a clinician. During the two-hour medically supervised session, people are encouraged to relax with an eye mask and noise cancelling headphones. Post-experience, clients will sit with their therapist to explore their individual journey and are then invited to recover further in a recovery lounge before heading home. Each individual’s experience is unique and personalized, with many reporting transformative experiences during the first few sessions.

Dr. Ryan Yermus, Field Trip Health’s Chief Clinical Officer, commented: “The initial clinical results from our first three centers have been extremely positive. The first patients in New York to complete the Field Trip Health course of treatment demonstrated a significant reduction in depressive symptoms from severe or moderately severe to mild or non-existent. This was further accompanied by a reduction in anxiety and trauma related symptoms. We are incredibly excited to bring this treatment to the people of Chicago.”

The entire experience is supported by Field Trip’s digital technology and tools that guide people through the experience from before treatment is approved until after their treatment program is complete, and beyond, with mood monitoring tools, meditations, mindfulness tools and information.

Field Trip Health centers are thoughtfully and intentionally designed to promote healing and provide people with a calming space before, during, and after treatment. The Chicago location was designed as a quiet escape from the busy city. Featuring a custom moss wall by local artist Stephanie Williams of Variegated Designs which brings a strong element of nature, where clients can relax and ground themselves amidst a palette of earth tones, soft velvets and natural light.

Ronan Levy, Field Trip’s Executive Chairman added: “With the opening of our Chicago location, we continue to execute against one of the pillars of our business strategy — building the infrastructure needed to deliver and scale best-in-class psychedelic therapies to our communities. With each new Field Trip Health center, we not only create incredible impact and healing, we are also building the know-how, protocols and understanding to further refine and enhance both the delivery of psychedelic medicine to people, as well as our development pipeline for new psychedelic therapeutics.”

The address for the Chicago clinic is 325 West Huron Street., Suite 603, Chicago, IL 60654 and patients can book a consultation by phone (1-888-519-6016), email (chicago@fieldtriphealth.com) or online at https://www.fieldtriphealth.com/locations/chicago.

About Field Trip Health Ltd.

Field Trip is the global leader in the development and delivery of psychedelic therapies. With Field Trip Discovery leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics, Field Trip Health hubs for psychedelic therapies opening across North America, and Field Trip Digital building the digital and technological tools to support psychedelic experiences and consciousness expansion, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://www.fieldtriphealth.com and https://www.meetfieldtrip.com.

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading